Peripheral T-cell lymphomas (PTCLs) represent approximately 12% of all lymphoid tumors worldwide. The vast majority of them belong to the not otherwise specified (NOS) angioimmunoblastic or ...

Favorable clinical responses have been demonstrated in cutaneous T-cell lymphoma with emerging evidence of clinical activity in other types of lymphoma and, to date, a good toxicity profile.

Get Instant Summarized Text (Gist) A clinical trial demonstrated that combining chemotherapy with immunotherapy significantly improves treatment outcomes for diffuse large B-cell lymphoma (DLBCL ...

SGX301 has led positive results in early-stage CTCL, with over 70% achieving treatment success in the phase 3 FLASH study. The phase 3 FLASH (NCT02448381) study evaluating SGX301 (HyBryte) has shown ...